Evotec (ETR:EVT) Share Price Crosses Below Fifty Day Moving Average – Time to Sell?

Shares of Evotec SE (ETR:EVT) crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of €4.11 and traded as low as €3.33. Evotec shares last traded at €3.36, with a volume of 632,201 shares changing hands.

Evotec Stock Performance

The business’s 50 day simple moving average is €4.11 and its 200 day simple moving average is €4.79. The company has a debt-to-equity ratio of 71.50, a current ratio of 2.33 and a quick ratio of 2.97. The company has a market capitalization of $622.69 million, a price-to-earnings ratio of -3.63, a price-to-earnings-growth ratio of 0.98 and a beta of 1.26.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.